Cholangiocarcinoma News

The Drug Pipeline for Cholangiocarcinoma

December 2021, Vol 2, No 4

At “The Pharma Pipeline” Roundtable during the 3rd Annual CCA Summit, experts from several pharmaceutical companies discussed recent and upcoming drugs in development for cholangiocarcinoma (CCA), emphasizing drug safety and a focus on patients.

Ying Bian, MD, Servier Pharmaceuticals, presented final data on the ClarIDHy phase 3 clinical trial in patients with CCA and IDH1 mutation whose disease progressed after 1 or 2 previous systemic regimens for advanced disease. Progression-free survival was significantly longer in patients randomized to ivosidenib compared with placebo (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.25-0.54; P <.001).

Because crossover was allowed after radiographic progression, the analysis for overall survival was adjusted by rank-preserving structural failure time. Patients receiving ivosidenib had significantly longer overall survival than those receiving a placebo (HR, 0.49; 95% CI, 0.34-0.70; P <.001). These data contributed to the FDA approval of ivosidenib (Tibsovo) for patients with CCA and IDH1 mutation who have received previous chemotherapy.

Neil Josephson, MD, Zymeworks, discussed HER2-targeted drugs in development. Zanidatamab is a bispecific HER2 antibody that is a cytotoxin-free approach investigated as monotherapy and in combination with standard-of-care therapy. The unique binding geometry of zanidatamab drives multiple mechanisms of action, including complement-dependent cytotoxicity, HER2 downregulation, and antibody-dependent cellular cytotoxicity and phagocytosis.

Results from a phase 1 study demonstrated that zanidatamab monotherapy is well-tolerated in the outpatient setting, with no treatment-related grade ≥3 adverse events. Antitumor responses included 40% confirmed partial responses and a 65% disease control rate.

In November 2020, the FDA granted zanidatamab a breakthrough therapy designation for patients with HER2-amplified biliary tract cancer after previous therapy.

Carl Dambkowski, MD, QED Therapeutics/Helsinn, discussed the development of infigratinib, a selective, FGFR1-3 kinase inhibitor, for FGFR2-driven CCA. Infigratinib (Truseltiq) received FDA approval in August 2021 for CCA with FGFR2 mutation.

The ongoing phase 3 PROOF clinical trial is comparing infigratinib versus gemcitabine plus cisplatin, with optional crossover to infigratinib. An amendment to the protocol will allow 1 cycle of gemcitabine-based therapy before randomization.

Additional studies with infigratinib are planned for earlier-stage CCA and for adjuvant therapy in urothelial carcinoma. Tissue-agnostic studies will investigate the broader application of FGFR inhibition with this new targeted therapy.

Valerie Jansen, MD, PhD, Elevation Oncology, discussed NRG1 fusions as rare, but potentially actionable, driver alterations across multiple tumor types. Seribantumab, an anti-HER3 monoclonal antibody, has a consistent and well-tolerated safety profile.

In a preclinical lung cancer model, treatment with seribantumab led to diminished tumor growth over time and increased tumor volume change at best response compared with vehicle plus afatinib. In a preclinical high-grade serous ovarian cancer model, complete or near-complete regression of all tumors was seen with clinically relevant doses of seribantumab.

The phase 2 CRESTONE clinical trial includes adults with locally advanced or metastatic solid tumors harboring an NRG1 fusion who have received ≥1 systemic therapies. Patients will receive seribantumab until disease progression or unacceptable adverse events.

Next steps in FGFR inhibitors include appropriate sequencing of patients and moving targeted therapy to earlier lines of treatment. There is a need to work together as a CCA research community. In particular, hybrid models of patient-centered care for early-phase clinical trials are needed. Moving from drug- or company-specific clinical trials to more patient-centric studies may save time and increase productivity.

Related Items

A Global Perspective on CCA
By Virote Sriuranpong, MD, PhD
Dr Virote Sriuranpong provides a perspective on key issues facing Thailand and other Asian countries in the prevention, screening, and early diagnosis of CCA.
Molecular Targets in iCCA Surgical Candidates
By Keri Lunsford, MD, PhD, FACS; Alice Wei, MD, MSc, FRCSC, FACS
Drs Keri Lunsford and Alice Wei provide their perspectives on how the molecular profile of iCCA patients can help direct surgery and locoregional therapy.
Periadjuvant Therapy in iCCA
By Cristina Ferrone, MD; Shishir Kumar Maithel, MD, FACS
Dr Cristina Ferrone discusses the use of adjuvant therapy, and Dr Shishir Kumar Maithel speaks to the role of neoadjuvant therapy in patients with iCCA.
New Frontiers in Surgery for CCA
By Skye Mayo, MD, MPH, FACS; Alice Wei, MD, MSc, FRCSC, FACS
Drs Alice Wei and Skye Mayo discuss options for induction therapy prior to surgery in iCCA.
Transplantation in iCCA
By Keri Lunsford, MD, PhD, FACS; Maria B. Majella Doyle, MD, MBA, FRCSI, FACS
Drs Keri Lunsford and Maria Majella Doyle explore clinical data on neoadjuvant treatment before transplantation in patients with iCCA.
Resistance Mechanisms and Adverse Events Associated with Targeted Therapy in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Dermatologic and ocular adverse events require appropriate and timely referral, and circulating tumor (ct) DNA analysis may not detect genomic fusions, as discussed in Session VI, “Molecularly Targeted Therapies in CCA,” at the 3rd Annual CCA Summit.
A Global Perspective on Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Experts from around the world emphasized the global burden of cholangiocarcinoma (CCA) during a Keynote Panel, “A Global Perspective on CCA: Perspectives on Research and Treatment from the US, EU, Latin America, and Asia” at the 3rd Annual CCA Summit.
The Cholangiocarcinoma Foundation 2021 Update
By Erin Burns, PhD
December 2021, Vol 2, No 4
Stacie Lindsey, Founder and CEO, Cholangiocarcinoma Foundation (CCF), delivered a Keynote Address during the 3rd Annual CCA Summit that centered on the need to work together and to focus on the patient in the development of platform studies for patients with cholangiocarcinoma (CCA) and the subsequent analysis of data. Ms Lindsey provided updates regarding the activities of CCF and recent and future activities.
Controversies in Resectable Intrahepatic Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Neoadjuvant approaches to cholangiocarcinoma (CCA) involve controversies and a lack of data. New clinical trials investigating protocols for hepatic artery infusion (HAI) pumps and liver transplant, were discussed during Session VIII, “New Frontiers in Surgery for CCA,” at the 3rd Annual CCA Summit.
Next-Generation Sequencing and Interventional Oncology in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
The benefits of next-generation sequencing, liquid biopsy, the need for integration of local and systemic therapies, advanced intraductal interventions, and advanced radiotherapy technologies in biliary tract cancers were addressed in Session VII, “Interventional Oncology and Locoregional Therapy,” at the 3rd Annual CCA Summit.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: